XML 22 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Apr. 02, 2021
Jan. 01, 2021
Current assets:    
Cash and cash equivalents $ 370,209 $ 319,217
Short-term investments 815,285 887,319
Trade receivables, net 177,673 160,875
Inventory 24,757 20,973
Prepaid expenses and other current assets 46,341 57,011
Total current assets 1,434,265 1,445,395
Long-term investments 328,860 330,751
Property and equipment, net 78,453 67,384
Deferred tax assets, net 160,598 156,711
Goodwill 63,684 63,684
Other long-term assets 124,682 73,408
Total assets 2,190,542 2,137,333
Current liabilities:    
Accounts payable 13,821 23,632
Accrued compensation and benefits 37,945 51,189
Accrued clinical trial liabilities 59,762 52,251
Rebates and fees due to customers 31,468 20,683
Accrued collaboration liabilities 13,461 12,456
Other current liabilities 56,880 44,447
Total current liabilities 213,337 204,658
Long-term portion of deferred revenues 9,760 3,755
Long-term portion of operating lease liabilities 52,837 49,086
Other long-term liabilities 3,421 721
Total liabilities 279,355 258,220
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 313,262 and 311,627 at March 31, 2021 and December 31, 2020, respectively 313 312
Additional paid-in capital 2,354,103 2,321,895
Accumulated other comprehensive income 2,740 4,476
Accumulated deficit (445,969) (447,570)
Total stockholders’ equity 1,911,187 1,879,113
Total liabilities and stockholders’ equity $ 2,190,542 $ 2,137,333